Advertisement
Document › Details
Merck KGaA. (6/15/17). "Press Release: Merck Expands Distribution Agreement with Public Health England". Darmstadt.
Region | ww excl Japan | |
Organisation | Merck KGaA | |
Group | Merck (DE) (Group) | |
Product | EBiSC (European Bank for induced pluripotent Stem Cells) | |
Merck today announced an expansion of its distribution alliance with Public Health England (PHE) to include the European Bank of induced pluripotent Stem Cells (EBiSC)
> Merck to become global distributor of the European Bank of iPS Cells, excluding Japan
> Extension of relationship with Public Health England for global distribution of cost-efficient, authenticated cell lines
Merck, a leading science and technology company, today announced an expansion of its distribution alliance with Public Health England (PHE) to include the European Bank of induced pluripotent Stem Cells (EBiSC)—a comprehensive iPS cell bank of more than 300 quality-controlled, disease-relevant, patient-derived human iPSC lines.
Merck provides a complete solution for the iPSC workflow, including novel reprogramming kits, iPSC culture media and stem cell antibodies and characterization kits. The addition of the EBiSC portfolio strengthens Merck’s existing distribution relationship with PHE as a distributor of its European Collection of Authenticated Cell Cultures (ECACC) portfolio.
“This partnership will give customers greater access to a comprehensive suite of human iPSCs for disease modeling,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “This is a great addition to our authenticated cell line portfolio and strengthens our offering across the iPSC workflow.”
Under the terms of the agreement, Merck will employ its sales, marketing and e-commerce expertise to distribute the EBiSC Human iPS Cell Bank. The distribution agreement includes all geographies except Japan. Financial details were not disclosed.
Following the acquisition of Sigma-Aldrich by Merck in 2015, the global distribution agreement became an important part of Merck’s life science business, driving growth in life science and offering premier brand tools for disease modeling and drug screening.
EBiSC is a European public-private partnership project designed to address the increasing demand by stem cell researchers for quality-controlled, disease-relevant, research-grade iPSC lines, data and cell services. Its goal is to establish a centralized European cell bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent high-quality tools for development of new medicines.
For more information, contact Karen Tiano
+49 6151 72 44461
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Record changed: 2023-06-05 |
Advertisement
More documents for Merck (DE) (Group)
- [1] Exscientia plc. (10/3/23). "Press Release: Exscientia Details Pipeline Prioritisation Strategy". Oxford....
- [2] Iktos S.A.S.. (3/9/23). "Press Release: Iktos Raises € 15.5m Series A Round to Expand Its Artificial Intelligence-based Drug Discovery Technologies and Solutions". Paris & Lausanne....
- [3] BioGeneration Ventures B.V.. (11/8/22). "Press Release: BGV Appoints Elena Ritsou as Venture Partner and Andree Blaukat as Senior Advisor". Amsterdam....
- [4] genOway S.A.. (9/8/22). "Press Release: Sigma-Aldrich and genOway Expand Their CRISPR/Cas9 Strategic Alliance". St. Louis, MO & Lyon....
- [5] iOmx Therapeutics AG. (10/5/21). "Press Release: iOmx Therapeutics Raises EUR 65 Million in Series B Round". Martinsried....
- [6] MoonLake Immunotherapeutics AG. (7/1/21). "Press Release: MoonLake Immunotherapeutics Appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO". Zug....
- [7] MoonLake Immunotherapeutics AG. (5/3/21). "Press Release: MoonLake In-licensing and Launch". Zug....
- [8] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
- [9] Merck KGaA. (7/1/20). "Press Release: Merck Advances Bioprocessing Capabilities with Raman Technology Sensor Acquisition". Darmstadt....
- [10] Scipio Bioscience S.A.S.. (2/25/20). "Press Release: Scipio Bioscience Raises €6.0 M Series A Financing". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top